Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Approval

Lecanemab

France Blocks Early Access to Alzheimer’s Drug Leqembi for Now

The health regulator says the trial benefit is too small to justify early availability.

Leqembi Launches in Germany for Early Alzheimer’s Patients

New Data Confirms Low Risk of Severe Side Effects for Alzheimer’s Drug Lecanemab

EU Approves First Alzheimer's Drug Targeting Disease Progression

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs